

**CORRECTION**

Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer

José J. G. Marin, Maria Giuseppina Prete, Angela Lamarca, Simona Tavolari, Ana Landa-Magdalena, Giovanni Brandi, Oreste Segatto, Arndt Vogel, Rocío I. R. Macias, Pedro M. Rodrigues, Adelaida La Casta, Joachim Mertens, Cecilia M. P. Rodrigues, Maite G. Fernandez-Barrena, Ana Da Silva Ruivo, Marco Marzioni, Giulia Mentrasti, Pilar Acedo, Patricia Munoz-Garrido, Vincenzo Cardinale, Jesus M. Banales, Juan W. Valle , John Bridgewater , Chiara Braconi and on behalf of the working group 6 of the COST-action 18122 (Euro-Cholangio-NET) as part of the European Network for the study of Cholangiocarcinoma (ENSCCA)

British Journal of Cancer (2021) 125:904; <https://doi.org/10.1038/s41416-020-01243-3>

Correction to: *British Journal of Cancer* (2020) **123**, 1047–1059; <https://doi.org/10.1038/s41416-020-0987-3>, published online 22 July 2020

Since the publication of this paper, the authors have noticed that acknowledgement of the support given by COST (European Cooperation in Science and Technology) to the study was omitted from the Funding section. The complete Funding information is provided below. The authors would like to apologise for this oversight. The original article has been corrected.

FUNDING INFORMATION

C.B. LKAS readership—University of Glasgow: J.J.G.M./R.I.R.M. Carlos III Institute of Health, Spain (PI16/00598); “Centro Internacional sobre el Envejecimiento”, Spain (OLD-HEPAMARKER, 0348-CIE-6-E); C.M.P.R. is supported by FEDER funds through the COMPETE programme and by national funds through Fundação para a Ciência e a Tecnologia (grants PTDC/MED-FAR/29097/2017 and SAICTPAC/0019/2015—LISBOA-01-0145-FEDER-016405). A.L. was part-funded by The Christie Charity. MGF-B is supported by grants SAF2014-54191-R and SAF2017-88933-R from FEDER/Ministerio

de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación; HEPACARE Project from Fundación La Caixa. J.M.B. was funded by Spanish Carlos III Health Institute (ISCIII) (FIS PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129), cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); AMMF (J.M. Banales and P.M. Rodrigues 2019/202); PSC Partners US; PSC Supports UK (06119JB); Horizon 2020 (H2020 ESCALON project: H2020-SC1-BHC-2018-2020); IKERBASQUE, Basque foundation for Science; CIBERehd (ISCIII); “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004), BIOEF (Basque Foundation for Innovation and Health Research); EITB Maratoya (BIO15/CA/016/BD); Department of Health of the Basque Country (2017111010) and Euskadi RIS3 (2016222001, 2017222014, 2018222029 and 2019222054); La Caixa Scientific Foundation (HR17-00601); “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to J.M. Banales and J.J.G. Marin). P.M.R. was funded by Spanish Carlos III Health Institute (ISCIII; Sara Borrell CD19/00254) cofinanced by “Fondo Europeo de Desarrollo Regional”. M.M. received PSA-2017-UNIVPM. P.A. is supported by a NIHR-Biomedical Research Centre funding (BRC646b/III/SP/101350). O.S. is funded by AIRC (IG2018, ID 21627, PI Segatto Oreste). A.V. is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - SFB/TRR 209 - 314905040, and Vo959/9-1. This work was performed under the frame of Working Group 6 of the COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu.

¹IBSAL, University of Salamanca, Salamanca, Spain; ²National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd), Carlos III National Health Institute, Madrid, ES, Spain; ³Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; ⁴Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center - IRCCS -, Rozzano (MI), Italy; ⁵Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; ⁶Division of Cancer Sciences, University of Manchester, Manchester, UK; ⁷Medical Oncology Unit, S. Orsola-Malpighi University Hospital, Bologna, Italy; ⁸Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain; ⁹Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum-University of Bologna, Bologna, Italy; ¹⁰Unit of Oncogenomics and Epigenetics, IRCCS Regina Elena National Cancer Institute, Rome, Italy; ¹¹Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany; ¹²Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; ¹³Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal; ¹⁴CIMA, University of Navarra, IdiNA, Navarra, Spain; ¹⁵Coimbra Hospital and University Centre (CHUC), Coimbra, Portugal; ¹⁶Università Politecnica delle Marche/Ospedali Riuniti di Ancona, Ancona, Italy; ¹⁷Institute for Liver and Digestive Health, University College London, London, UK; ¹⁸Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Copenhagen, Denmark; ¹⁹La Sapienza University, Rome, Italy; ²⁰IKERBASQUE, Basque Foundation for Science, Bilbao, Spain and ²¹UCL Cancer Institute, London, UK

Correspondence: Chiara Braconi (chiara.braconi@glasgow.ac.uk)

Published online: 5 July 2021